Stock REXAHN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Rexahn Pharmaceuticals, Inc. Share Price Nyse

Equities

US7616401011

Biotechnology & Medical Research

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Rexahn Pharmaceuticals, Inc.

Press releases Rexahn Pharmaceuticals, Inc.

Ocuphire Pharma : to Participate in Upcoming Virtual HCW Conference in November AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) AQ
Rexahn Pharmaceuticals : Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP AQ
Rexahn Pharmaceuticals : Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma AQ
REXAHN PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K) AQ
More press releases

Company Profile

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock
  4. Stock